|
|
| Biotechnologies Et Génétique > Etude de marché sectorielle |
|
|
|
|
€ 2 219,00 |
Editeur
: |
Visiongain |
Langue
: |
Anglais |
Date de publication : |
Juin 2006 |
Taille du document : |
147 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
03-026: The Market for Tissue Microarrays
134 pages | Juillet 2003 |
This report provides vital information on end-users’ scientific objectives, instrumentation for production and analysis of TMAs, outsourcing practices and preferred TMA suppliers |
640,00 €
|
| |
| |
Human Cloning: Economics and Ethics
36 pages | Mars 2003 |
Human cloning has moved from science-fiction novels, to science laboratories.
Pro-human cloning companies are racing to create the first cloned child, or make a breakthrough in stem cell research, |
850,00 €
|
| |
| |
Chinese Markets for Biotechnology
153 pages | Janvier 2002 |
China's demand for biotechnology has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic t |
2 835,00 €
|
| |
| |
03-018: Market Opportunities in Cytokine & Growth Factor Research
170 pages | Mai 2003 |
This report identifies preferred quantification and activity assays, new research trends and the most popular suppliers of antibodies, recombinant proteins and DNA microarrays |
800,00 €
|
| |
| |
Target and Lead Validation
160 pages | Décembre 2000 |
The advent of brute force approaches to lead generation has highlighted a key bottleneck in drug development.
The issue is not how many new compounds can one make per day, but rather how many c |
1 400,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Bioinformatics
150 pages | Décembre 2000 |
Automation has assaulted several levels of biological research generating vast amounts of data.
Great leaps in DNA sequencing technology and automation led to a dramatic increase in sequence th |
1 400,00 €
|
| |
| |
Revolutionise Drug Discovery through Genomics & Proteomics Study
10 pages | Novembre 2002 |
Genomics and Proteomics are complementary technologies of biological research.
The potential of these technologies for biomedical revolution will be realized by integrating them into the drug disc |
200,00 €
|
| |
| |
Chinese Markets for Biotechnology
153 pages | Janvier 2002 |
China's demand for biotechnology has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic t |
3 500,00 €
|
| |
| |
04-001: Evaluating Online Advertising Opportunities @ Life Science Portals
176 pages | Février 2004 |
This report will help life science executives decide where to spend their advertising budget using the same criteria as their scientific customers, rather than assessing the value of a portal on the b |
1 120,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
|
|
The purpose of this visiongain report is to examine the commercial prospects of nanotechnology in medicine – the fast-developing and increasingly lucrative field of nanomedicine. Nanotechnology has great potential to benefit - even revolutionise - the pharmaceutical, medical devices, diagnostics and imaging sectors. Visiongain predicts that nanomedicine will exhibit strong growth in all sectors from 2006-2011, leading to multi-billion dollar revenues. Key technology platforms such as nanocrystals, nanotubes, dendrimers, fullerenes, quantum dots and molecular scaffolding will drive that market expansion.
Nanomedicine 2006-2011 examines the nanomedical sector critically through comprehensive primary and secondary research, including interviews with key figures in industry and academia, reports and policy documents, nanotechnology conference proceedings, business/industry news and consultation with bodies promoting nanotechnology. Visiongain applied techniques such as financial forecasting, SWOT analysis and qualitative projections to provide a comprehensive market report with detailed analyses and informed opinion.
In particular, this report concentrates on the following essential aspects of nanotechnology in the healthcare industry:
Technologies that drive nanomedicine
Key players in nanomedicine
Revenue trends for nanotechnology in healthcare between 2006-2011
Projected timetables for major developments up to 2020
Drivers and opportunities in nanomedicine
Restraints and threats in nanomedicine
Funding and governmental policy in nanomedicine
Venture capital in nanomedicine
Regulation, safety and ethics of nanotechnology in medicine
An assessment of relevant business models and issues
A geographical breakdown of the world market for nanomedicine in 2011
Why you should buy this report
To receive a comprehensive analysis of the prospects of the world nanomedical sector from 2006-2011
To find out predicted revenues, growth rates and market shares for sectors within nanomedicine from 2006-2011
To determine the forces that influence nanotechnology with medical applications:
Competitive characteristics of the market
Regulatory, funding and societal issues
Drivers and restraints
Strengths, weaknesses, opportunities and threats
To find out where nanotechnology in medicine is heading - both technologically and commercially - in the mid-to-long-term periods as well
|
|
|
PPLSEN
|
|
|
|
|
